share_log

莎普爱思(603168.SH):盐酸西替利嗪滴眼液获得临床试验批准通知书

Zhejiang Shapuaisi Pharmaceutical (603168.SH): The hydrochloride cetirizine eye drops have received a clinical trial approval notice.

Gelonghui Finance ·  Dec 9, 2024 01:16

Gelonghui on December 9th, zhejiang shapuaisi (603168.SH) announced that the company's levocetirizine hydrochloride eye drops obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (Notice No.: 2024LP02825), and the company plans to conduct clinical trials after the conditions are met. This product is used to treat eye itching associated with allergic conjunctivitis.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment